



Published in final edited form as:

*Mod Pathol.* 2021 June ; 34(6): 1203–1212. doi:10.1038/s41379-021-00744-7.

## Recurrent *MEIS1-NCOA2/1* Fusions in a Subset of Low-Grade Spindle Cell Sarcomas Frequently Involving the Genitourinary and Gynecologic Tracts

Yu-Chien Kao<sup>1,2</sup>, Jennifer A. Bennett<sup>3</sup>, Albert J. H. Suurmeijer<sup>4</sup>, Brendan C. Dickson<sup>5</sup>, David Swanson<sup>5</sup>, Pankhuri Wanjari<sup>3</sup>, Lei Zhang<sup>6</sup>, Jen-Chieh Lee<sup>7</sup>, Cristina R. Antonescu<sup>6</sup>

<sup>1</sup>Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.

<sup>2</sup>Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. <sup>3</sup>Department of Pathology, University of Chicago Medical Center, Chicago, IL, USA. <sup>4</sup>Department of Pathology, University Medical Center, Groningen, University of Groningen, Groningen, The Netherlands <sup>5</sup>Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada. <sup>6</sup>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. <sup>7</sup>Department and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

### Abstract

Sarcomas with *MEIS1-NCOA2* fusions have been so far reported in 2 cases each of primitive renal sarcomas and intraosseous pelvic rhabdomyosarcomas. Their histologic spectrum, anatomic distribution, and clinical behavior remain poorly defined. In this study, we report 6 additional spindle cell sarcomas with *MEIS1-NCOA2* or *NCOA1* fusions that fall into the same disease spectrum with the previously reported renal sarcomas. The patients' age range was wide (20–76 years, mean 46) and all except one were female. The tumors arose in the kidney (n=2), and one each in the uterine corpus, vagina, scrotum, and para-rectal region. The consistent morphology was that of monomorphic spindle to ovoid cells in a storiform, whorling, or solid pattern.

Alternating cellularity, myxoid stroma, and microcystic changes were seen in some cases. Mitotic activity varied greatly (<1–33/10 high power fields). The immunophenotype was non-specific, with most cases expressing variable degrees of TLE1, WT1, cyclin D1, CD56, and CD10. Using various platforms of RNA-based targeted sequencing, *MEIS1-NCOA2* fusions were recurrently identified in 5 cases, and a novel *MEIS1-NCOA1* fusion was found in one renal tumor. The gene fusions were validated by fluorescence in situ hybridization using custom BAC probes. Of the 5 patients with available follow-up (5 months to 8 years), all experienced local recurrences, but no distant spread or death from disease. Our results expand the clinicopathologic spectrum of sarcomas with *MEIS1-NCOA2/1* fusions, providing evidence of an undifferentiated spindle cell phenotype with non-specific immunoprofile and low-grade clinical behavior.

**Correspondence:** Cristina R. Antonescu, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, antonesc@mskcc.org, Jen-Chieh Lee, M.D., Ph.D., Department and Graduate Institute of Pathology, National Taiwan University, Hospital, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei, 10002, Taiwan, leejenchieh@ntuh.gov.tw.

**Conflict of interest:** None to declare

## Keywords

sarcoma; MEIS1; NCOA2; NCOA1; gene fusions

---

## INTRODUCTION

*MEIS1-NCOA2* fusions have been recently described in a handful of spindle cell sarcomas, including 2 cases each of primitive sarcomas of the kidney and intraosseous rhabdomyosarcomas (RMS).[1, 2] The renal tumors displayed a monomorphic spindle cell cytomorphology with alternating cellularity, arranged in a fascicular or whorling growth pattern. Due to their primitive-appearing round to fusiform nuclei and scant cytoplasm, the tumors resembled synovial sarcomas, BCOR family sarcomas, malignant peripheral nerve sheath tumors, and *NTRK* fusion tumors. Unlike the RMS with *MEIS1-NCOA2* fusions showing convincing myogenic markers, these primitive renal sarcomas have a non-specific immunoprofile, with positive CD56, focal WT-1, focal ER, and variable TLE1 and cyclin D1 staining. Based on their primitive morphology and undetermined histogenesis, their diagnosis remains challenging without molecular analysis. Moreover, as only 2 cases have been so far reported, their clinical behavior remains unclear based on the limited follow-up available and it is unknown whether this family of tumors is restricted to the kidneys.

In this study, we expand our understanding of tumors characterized by *MEIS1-NCOA2* fusions by investigating the clinicopathologic and molecular findings of 6 new cases of spindle cell sarcomas with extended clinical follow-up, arising from various organs, including the uterus, vagina, scrotum, para-rectal soft tissue, and kidney. Moreover, we also report an additional spindle cell RMS with *MEIS1-NCOA2* fusion arising in the vulva, representing the first extraosseous RMS with this fusion.

## MATERIALS AND METHODS

### Case selection

The cases were retrieved from the consultation files and institutional archives of the authors (C.R.A. and J.C.L.). Six sarcomas with *MEIS1-NCOA2* or *MEIS1-NCOA1* fusions were collected. These cases were submitted for various RNA sequencing methods either at the time of diagnosis to provide information for further tumor classification and potential treatment guidance or during retrospective case review for translocation-associated sarcomas. The hematoxylin and eosin stained slides and the immunohistochemical stains were reviewed. Clinicopathologic parameters, including relevant clinical history, age, gender, tumor location, tumor size, and follow-up information, were collected from the pathologic reports and electronic medical record. This study was approved by the institutional review board.

### RNA sequencing

The samples were investigated on different targeted RNA sequencing platforms, including University of Chicago Medicine OncoPlus next-generation sequencing (n=1, case 1), TruSight RNA Fusion Panel (Illumina, San Diego, CA) (n=3, cases 2–4), and Archer

FusionPlex Custom Solid Panel (n=2, cases 5–6), using formalin-fixed paraffin-embedded (FFPE) tissues. The above gene panels include 1213, 507, and 85 cancer-related genes, respectively, with *NCOA2* and *NCOA1* genes being included in all three panels. The detailed methods have been described previously.[1–3] In addition, case 1 was also submitted to FoundationOne CDx (Cambridge, MA) for mutation discovery and copy number assessment.

### Fluorescence in situ hybridization (FISH)

FISH for *NCOA2* and *MEIS1* was performed using custom designed probes made by BACs flanking respective genes as previously described to validate the fusions.[1, 2] BAC clones were selected based on the information on UCSC genome browser (<http://genome.ucsc.edu>) and obtained from BACPAC sources of Children’s Hospital of Oakland Research Institute (CHORI) (Oakland, CA) (<http://bacpac.chori.org>) and Life Technologies Corporation (Carlsbad, CA). After plasmid DNA extraction and nick translation, the probes were validated on metaphases. Four µm-thick FFPE tissue sections of our cases were pretreated and hybridized with the probes.

### Immunohistochemistry

Most of the immunohistochemical stains were performed at the time of diagnosis and therefore were based on the differential diagnoses of each case. The immunostained slides were reviewed and results summarized in Supplementary Table 1. After the identification of the gene fusion, an additional *NCOA2* immunohistochemical stain (1:500, LS-B12201, Lifespan Biosciences, Seattle, WA) was performed on case 2. Retrospective *MDM2* staining was also performed after the identification of *MDM2* gene amplification in case 1.

## RESULTS

### Spindle cell sarcomas with *MEIS1-NCOA2/1* fusions have a predilection for the genitourinary tract and gynecologic organs

A total of 6 cases, including 5 with *MEIS1-NCOA2* fusions and one with *MEIS1-NCOA1*, were included in the study. Interestingly, all tumors arose within the abdominal cavity or pelvis and involved various organs, including 2 in the kidneys and one each in the uterine corpus, vagina, scrotum (involving dermis to subcutis), and para-rectal soft tissue. There were 5 females and one male, with a wide age range at diagnosis of 20–76 years (mean: 46, median: 44). The 76-year-old patient presented with a recurrent scrotal tumor years after resection of the primary tumor, and the age at the primary resection was unknown. The primary tumors ranged from 11 to 21 cm (mean: 17). The clinicopathologic features of the study group, along with those of the 2 previously reported kidney cases,[1] were summarized in Table 1.

Two patients had available preoperative history. Case 2, a 35-year-old woman, had been receiving ovulation induction medication, including clomiphene, r-hFSH, and chorionic gonadotropin, for 8 months in an infertility clinic before a hemorrhagic vaginal mass was identified. Another patient (case 4) was a 38-year-old woman with an intrapelvic para-rectal

tumor that was present for 2 years and enlarged during pregnancy. She received surgical removal of the tumor one month after delivery.

### ***MEIS1-NCOA2/1* fusion sarcomas show primitive round to spindle cells with whorling and storiform patterns and alternating cellularity**

The tumor borders were unencapsulated and focally infiltrative (cases 1 and 3) or relatively well circumscribed (case 6). Histologically, most tumors showed primitive, monomorphic spindle to ovoid cells with scant cytoplasm, arranged in short fascicular, vague whorling, storiform and/or solid patterns (Figs. 1–2). Cases 1, 2 and 6 showed alternating cellularity, with myxoid to hyalinized stroma in the hypocellular area (Fig. 1A–D, 2G). Necrosis was present in 2 renal cases. Mitotic activity ranged from <1–33 per 10 high power fields (HPFs), with 4 cases having 10/10HPFs and 2 mitotically active cases in the uterus (33/10HPFs) and kidney (25/10 HPFs).

In addition to this predominant histomorphology, the tumors showed a spectrum of appearances. Case 1 also had areas of cellular aggregates of primitive cells (Fig. 1B), reminiscent of the primitive cell clusters described in the previously reported *MEIS1-NCOA2* renal sarcomas.[1] Case 2 was highly vascular displaying a rich capillary network (Fig. 1D) and scattered thick-walled vessels, and had prominent areas of hemorrhagic change. A few multinucleated tumor giant cells were noted. Case 4 was composed of sheets of ovoid cells with convoluted nuclei, vesicular chromatin and small nucleoli, and interspersed microcystic spaces (Fig. 2D). Case 5 showed mostly uniform cells, but also exhibited areas of increased pleomorphism and hyperchromasia (Fig. 2F). In highly cellular areas of case 6, the tumor cells appeared more rounded, and epithelioid cells were seen in the second recurrence (Fig. 2H).

### **Sarcomas with *MEIS1-NCOA2/1* fusions are characterized by a non-specific immunoprofile.**

Immunohistochemically, these tumors had a non-specific phenotype, with variable degree of staining for TLE1, WT1, cyclin D1, CD56, and CD10, ranging from diffuse to focal (Supplementary Table 1). Variable ER (2 of 4) and CD99 (2 of 3) expressions were also seen in some cases. Myogenic markers were mostly negative, except for focal desmin staining in the 2 renal tumors, focal smooth muscle actin in the uterine tumor, and diffuse caldesmon expression in the scrotal tumor. All cases tested for myogenin were negative.

Other negative markers included BCOR (n=3), AE1/AE3 (n=5), EMA (n=3), S100 (n=5), SOX10 (n=3), CD34 (n=3), CD117 (n=4),  $\alpha$ -inhibin (n=3), ALK (n=3), HMB45 (n=3), H3K27me3 (retained, n=2), ERG (n=2), and PAX8 (n=2). *NCOA2* immunostaining was performed in one case (case 2) and showed diffuse moderate staining (Fig. 1F). Pan-Trk staining (EPR17341) was performed in case 3 and was diffusely positive, but no gene rearrangement for *NTRK1-3* was found by FISH and the subsequent targeted RNA sequencing. Pan-Trk staining was subsequently tested on 3 other cases and multifocal moderate expression was found in one (case 2).

The original diagnoses rendered in these tumors included undifferentiated uterine sarcoma, low-grade endometrial stromal sarcoma, low-grade sarcoma, not otherwise specified (NOS), undifferentiated spindle cell sarcoma, and sarcoma, NOS (Table 1).

### **MEIS1-NCOA2/1 fusions identified by RNA sequencing**

RNA Sequencing identified *MEIS1-NCOA2* fusion in 5 cases, with exon 6 of *MEIS1* (NM\_002398.2) fused to exon 12 of *NCOA2* (NM\_001321703.1) (n=3) or exon 7 of *MEIS1* fused to exon 13 or 14 of *NCOA2* (n=2) (Table 1, Fig. 3A). The latter fusion junction was identical to the previously reported kidney tumor.[1] Another patient (case 5) had an alternative 3' fusion partner gene, with a novel *MEIS1* exon 7-*NCOA1* (NM\_003743) exon 13 fusion. All the fusion transcripts were predicted to be in-frame. FISH confirmed the translocations, showing break-apart of *MEIS1* and *NCOA2* genes (Fig. 3B–C).

In case 1 (uterine tumor), additional genetic alterations identified by FoundationOne CDx (Cambridge, MA) included *CTNNB1* S33C, *MDM2* amplification, *ATRX* C280fs\*3, and *MPL* Y252H. Retrospective immunostains showed aberrant nuclear expression of beta-catenin and MDM2 (~70%) expression. Tumor mutational burden was 3 muts/Mb. Immunohistochemical stain for beta-catenin was performed on three other cases (cases 2–4) and were all negative for nuclear staining. MDM2 was also tested by immunohistochemistry in the remaining 5 cases and by FISH in 2 (cases 2, 5), which all showed negative results for MDM2 overexpression or amplification.

### **MEIS1-NCOA2/1 fusion-positive sarcomas share a low-grade malignant potential**

Five patients had available follow-up, ranging from 5 months to 8 years (Table 1). All 5 patients developed local recurrences, with 3 of them having multiple recurrences over the years. None developed distant metastases or died of disease at last follow-up. The follow-up information of each patient is as follows:

Patient 1 presented with a uterine tumor and underwent total hysterectomy and bilateral salpingo-oophorectomy. The primary tumor involved the uterine corpus without extending to the cervix or adnexae. During surgery, however, there were extensive adhesions, resulting in intraoperative rupture of the tumor. Follow-up computed tomography scan at 5 months after diagnosis showed multiple mesenteric masses. Biopsy of the mass confirmed recurrent disease.

Patient 2 was managed with an intralesional excision for a primary vaginal mass and subsequently developed multiple local recurrences 3 months, 1.5 years, and 7 years later. No metastasis was found at last gynecologic follow-up (7 years). The patient was still alive 10 years after the initial diagnosis, with unknown disease status.

Patient 3 was a male patient with a small recurrent scrotal lesion (6 mm), with the primary lesion had been excised years ago.

Patient 4 presented with a para-rectal tumor and subsequently developed multiple intrapelvic recurrences which were surgically removed multiple times (4, 6, and 8 years after initial diagnosis). The uterus and left ovary removed were free of tumor. The patient was still alive 12 years after the initial diagnosis, with unknown disease status.

Patient 6, a 50-year-old woman, had a large tumor replacing most of the right kidney. The tumor was confined to the renal capsule, without invading the perinephric fat, the renal

sinus, or the renal vein. She underwent total nephrectomy and removal of a portion of 10<sup>th</sup> rib. One and a half years post surgery, she developed a local recurrence in the retroperitoneum, which was removed surgically and the additionally sampled margins were free from tumor. However, six years after initial diagnosis, she developed a second recurrence involving the right retrocaval region and right chest wall/diaphragm, which was also resected.

### Vulvar spindle cell RMS with *MEIS1-NCOA2* fusion

During our case selection, we also identified the first extra-osseous spindle cell RMS with *MEIS1-NCOA2* fusion. The patient was a 33-year-old woman with an enlarging vulvar tumor for 2 years. Microscopically, the tumor showed spindle cells with increased mitotic activity arranged in fascicles (Fig. 4A), accompanied by focal larger tumor cells with eosinophilic cytoplasm (Fig. 4B), some multinucleated cells, and tumor-infiltrating mast cells. Unlike other *MEIS1-NCOA2* tumors in this study group, this tumor expressed multiple myogenic markers including desmin, caldesmon, myogenin, MyoD1, focal calponin and smooth muscle myosin heavy chain. ER was also positive. Other stains performed retrospectively included MDM2, beta-catenin, pan-Trk, ALK, and p53 and were all negative. Targeted panel of RNA sequencing (Archer FusionPlex) identified a similar fusion of *MEIS1* exon 7 to *NCOA2* exon 13. The fusion was confirmed by break-apart FISH for *MEIS1* and *NCOA2* genes. The tumor involved the initial excisional margin, and the patient received a re-resection after neoadjuvant therapy. A small residual tumor (0.6 cm) with negative margins was noted. This was a recent case and no follow-up data was available.

## DISCUSSION

In this study, we report 6 undifferentiated spindle cell sarcomas harboring *MEIS1-NCOA2/1* fusions, demonstrating that these tumors can occur not only in the kidneys, but also in other locations, such as uterus, vagina, scrotum, and para-rectal soft tissues. Similar to the *YWHAE* gene fusions in high-grade endometrial stromal sarcomas and clear cell sarcoma of kidney, sarcomas with *MEIS1-NCOA* fusions identified in this study also show a predilection for the gynecologic and genitourinary tracts. These neoplasms show a spectrum of histomorphology from monotonous spindle cells arranged in whorls or a storiform pattern with alternating cellularity to sheets of ovoid cells with microcystic change. Due to a non-specific immunoprofile, many of the cases remained initially unclassified, being designated as undifferentiated sarcomas.

The differential diagnosis can be broad and depends on the location and histomorphology of individual tumors. For example, those in the kidneys can mimic synovial sarcoma, BCOR family of tumors, metanephric stromal tumor, or mixed epithelial stromal tumor of kidney. TLE1 expression in these tumors further simulates the immunoprofile of synovial sarcoma and BCOR family of tumors. Compared to sarcomas with *MEIS1-NCOA* fusions, synovial sarcomas typically are more uniformly hypercellular with elongated spindle cell fascicles. TLE1 staining is usually diffusely positive in synovial sarcoma, while it is more variable in sarcomas with *MEIS1-NCOA* fusions. BCOR immunoreactivity is observed in one of the

two previously reported renal sarcomas with *MEIS1-NCOA2*, with moderate intensity in ~60% of the tumor cells.[1] In this study, three additional cases were tested for BCOR and all showed negative results (cases 1–3), suggesting that BCOR immunoreactivity is present in only a minority of sarcomas with *MEIS1-NCOA* fusions.

Sarcomas with *MEIS1-NCOA* fusions involving the gynecologic organs are most likely to be misdiagnosed as endometrial stromal sarcoma or undifferentiated uterine sarcoma. Case 1 showed a mitotically active uterine tumor with a primarily pushing border and only focally irregular interface with the myometrium and a CD10+/cyclin D1 focally+/ BCOR –/ ER – immunoprofile. The tumor was negative for *BCOR*, *JAZF1*, *PHF1*, and *YWHAE* rearrangements by FISH and was classified as an undifferentiated uterine sarcoma. Case 2, a vaginal tumor, showed a low-grade spindle cell sarcoma morphology with a whorling pattern accompanied by rich vasculature. The tumor was intra-lesionally excised, and therefore the tumor border could not be evaluated. The tumor was positive for ER and focally positive for CD10. FISH study was not available at the time of initial diagnosis. It was classified as a low-grade endometrial stromal sarcoma based on morphology and immunohistochemistry. In the gynecological tract, a small subset of sarcomas, be it ER-positive or -negative, do not fit into the common groups of low-grade and high-grade endometrial stromal sarcomas, both morphologically and genetically. Few examples of lesions associated with rare gene fusions include sarcomas harboring *NTRK*, *PDGFB*, and *MEIS1-NCOA* fusions, which can be encountered in the gynecologic tract as well other locations.

For tumors involving superficial soft tissues, such as case 3 in the scrotum, the storiform pattern and monotonous short spindle cells raised the possibility of dermatofibrosarcoma protuberans. However, CD34 stain and FISH for *PDGFB* and *PDGFD* gene abnormalities were negative. The positive pan-Trk immunostaining triggered FISH for *NTRK1–3* gene rearrangements, which were all negative. This tumor was therefore classified as a low-grade sarcoma, not otherwise specified.

These cases illustrate that in unclassifiable low-grade spindle cell sarcomas, especially those with alternating cellularity and whorling or storiform patterns, the nonspecific panel of TLE1, WT1, cyclinD1, CD56 and CD10 may point the need for further molecular testing such as targeted RNA sequencing or FISH for *NCOA2*.

*NCOA2* gene encodes a nuclear hormone receptor transcriptional coactivator. Gene fusions involving *NCOA2* with other partner genes have been identified in several distinct groups of mesenchymal tumors, including mesenchymal chondrosarcoma (*HEY1-NCOA2*),[4] soft tissue angiofibroma (*AHRR-NCOA2*),[5] congenital/infantile spindle cell RMS (*VGLL2-NCOA2*, *SRF-NCOA2*, *TEAD1-NCOA2*),[6] biphenotypic sinonasal sarcoma (*PAX3-NCOA1/2*),[7, 8] *PRRX-NCOA1/2* rearranged fibroblastic neoplasm,[9] and uterine tumor resembling ovarian sex cord tumor (*ESR1-NCOA2/3*, *GREB1-NCOA1/2*).[10] Our uterine case did not show sex-cord-like differentiation as seen in uterine tumor resembling ovarian sex cord tumor. Each of these tumors has unique clinicopathologic features distinct from the low-grade spindle cell sarcomas with *MEIS1-NCOA2/1* fusions reported in this study.

NCOA2 immunostain was positive in case 2, the only case tested. A previous study in soft tissue angiofibroma showed that NCOA2 (polyclonal; ITK Diagnostics BV, Uithoorn, The Netherlands) was positive not only in soft tissue angiofibromas but also in other spindle cell lesions without *NCOA2* fusions, such as intramuscular myxoma, myxoid liposarcoma, myxofibrosarcoma, solitary fibrous tumor, schwannoma, gastrointestinal stromal tumor, etc., and therefore does not serve as a good screening marker.[11]

In this study, a novel *MEIS1-NCOA1* fusion was identified in a kidney sarcoma as an alternative fusion to *MEIS1-NCOA2*. The breakpoint of *MEIS1* exon 7 fused to *NCOA1* exon 13 is the same as one of the common fusion variants of *MEIS1-NCOA2* fusions, and both preserve the C-terminal transcription activation domains of NCOA proteins in the deduced chimeric MEIS1-NCOA protein. Similar interchangeable role of *NCOA1* and *NCOA2* fusions has also been observed in other tumors, such as biphenotypic sinonasal sarcoma (*PAX3-NCOA1/2*),[7, 8] *PRRX-NCOA1/2* rearranged fibroblastic neoplasm,[9] and uterine tumor resembling ovarian sex cord tumor (*GREB1-NCOA1/2*).[10]

In addition to the *MEIS1-NCOA2* fusion, case 1, a uterine sarcoma, was also identified to have co-existing *CTNNB1* mutation and *MDM2* amplification, among other genetic changes. As these changes were only identified in a single case of *MEIS1-NCOA2* fusion sarcoma, their pathogenetic contributions are uncertain. In uterine sarcomas, *CDK4* and/or *MDM2* amplifications are recurrent genetic events in *BCOR*-rearranged uterine sarcoma (38% *CDK4* and 45–100% *MDM2* amplifications) and Müllerian adenosarcoma (22–37.5% *CDK4* and 11–31% *MDM2* amplifications).[12–17] Whether the same is true for sarcomas with *MEIS1-NCOA* fusions awaits further research. The significance of *CTNNB1* mutations in uterine sarcomas is also unclear although activating *CTNNB1* mutations have been reported in rare uterine sarcomas and activation of Wnt signaling pathway is observed in low-grade endometrial stromal sarcomas.[18, 19]

In this study, we provided an extended follow-up data demonstrating that these tumors have at least a low-grade malignant potential. The clinical courses of these patients were characterized by multiple local recurrences even years after the initial operation, suggesting that long-term follow-up is needed. Moreover, since only limited follow-up was available for our two mitotically active cases in this study (cases 1 and 5), it remains to be seen if there will be a high-grade subset of *MEIS1-NCOA* sarcomas with more aggressive clinical behavior that can be predicted by certain histologic parameters. Our case 1 had intraoperative rupture of the uterine tumor and later developed mesenteric locoregional recurrence/metastasis. Distant metastasis was not observed during the relatively short follow-up period (5 months). Case 5 was a renal tumor with areas of increased pleomorphism, hyperchromasia, and brisk mitotic activity. However, no follow-up information was available for this patient.

Lastly, we also describe the first extrasosseous spindle cell RMS with *MEIS1-NCOA2* fusion involving the vulva. Like the previous 2 intraosseous spindle cell RMS with *MEIS1-NCOA2* fusions in the iliac bones of 22- and 39-year-old patients, this tumor also occurred in a young adult patient (33 years old). It also showed a similar histomorphology to the previously reported intraosseous cases, with hypercellular and monotonous spindle cells in



intersecting short fascicles.[2] No rhabdomyoblastic type cells were noted on H&E. Immunohistochemically, it demonstrated multiple myogenic markers including desmin, caldesmon, myogenin, and MyoD1, indicating rhabdomyoblastic differentiation. In contrast, our study group of undifferentiated tumors with *MEIS1-NCOA* fusions showed very limited expressions of myogenic markers, with only focal desmin (cases 5 and 6), focal smooth muscle actin (case 1) or sole caldesmon staining (case 3). None of the 5 cases tested was positive for myogenin. The fusion junctions of *MEIS1* and *NCOA2* were similar in cases with or without rhabdomyoblastic differentiation, with in-frame fusions of *MEIS1* exon 6 to *NCOA2* exon 12 or *MEIS1* exon 7 to *NCOA1/2* exon 13 or 14. Currently, the clinical follow-up and treatment response of RMS with *MEIS1-NCOA2* fusions are still unclear.

In conclusion, undifferentiated spindle cell sarcomas with *MEIS1-NCOA* fusions can occur in a variety of different anatomic locations in the genitourinary tract and gynecologic organs. In addition to the typical monomorphic spindle cell morphology with whorling or a storiform pattern and alternating cellularity, some cases may show a wider spectrum of morphology, including sheets of ovoid cells, microcystic change, and increased nuclear pleomorphism. *MEIS1-NCOA2* fusions are the predominant fusion type, and a minority of cases may harbor the alternative *MEIS1-NCOA1* fusion. Clinical follow-up suggests a low-grade malignant behavior with multiple local recurrences of these tumors.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENT


The authors would like to thank Jeremy P. Segal (University of Chicago Medical Center) for assistance in analyzing the RNA sequencing results (case 1). This work is partly supported by P50 CA 140146-01, P30 CA008748, Cycle for Survival, St Baldrick Foundation, and Kristin Ann Carr Foundation granted to CRA, TMU108-AE1-B20 granted to YCK by Taipei Medical University, and 108-S4295 granted to JCL by National Taiwan University Hospital.

**Supported by:** P50 CA 140146-01 (CRA), P30 CA008748 (CRA), Cycle for Survival (CRA), St Baldrick Foundation (CRA), Kristin Ann Carr Foundation (CRA), TMU108-AE1-B20 (YCK), NTUH108-S4295 (JCL).


## REFERENCES

1. Argani P, Reuter VE, Kapur P, Brown JE, Sung YS, Zhang L, et al. Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney. *Am J Surg Pathol*. 2018;42:1562–70. [PubMed: 30179902]
2. Agaram NP, Zhang L, Sung YS, Cavalcanti MS, Torrence D, Wexler L, et al. Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype. *Am J Surg Pathol*. 2019;43:695–702. [PubMed: 30720533]
3. Bennett JA, Ritterhouse LL, Furtado LV, Lastra RR, Pesci A, Newell JM, et al. Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases. *Mod Pathol*. 2020;33:734–47. [PubMed: 31591497]
4. Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. *Genes Chromosomes Cancer*. 2012;51:127–39. [PubMed: 22034177]
5. Jin Y, Moller E, Nord KH, Mandahl N, Von Steyern FV, Domanski HA, et al. Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma

- results in upregulation of aryl hydrocarbon receptor target genes. *Genes Chromosomes Cancer*. 2012;51:510–20. [PubMed: 22337624]
6. Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, et al. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. *Am J Surg Pathol*. 2016;40:224–35. [PubMed: 26501226]
  7. Huang SC, Ghossein RA, Bishop JA, Zhang L, Chen TC, Huang HY, et al. Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. *Am J Surg Pathol*. 2016;40:51–9. [PubMed: 26371783]
  8. Le Loarer F, Laffont S, Lesluyes T, Tirode F, Antonescu C, Baglin AC, et al. Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. *Am J Surg Pathol*. 2019;43:747–54. [PubMed: 30829729]
  9. Lacambra MD, Weinreb I, Demicco EG, Chow C, Sung YS, Swanson D, et al. PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. *Genes Chromosomes Cancer*. 2019;58:705–12. [PubMed: 31008539]
  10. Goebel EA, Hernandez Bonilla S, Dong F, Dickson BC, Hoang LN, Hardisson D, et al. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A Morphologic and Molecular Study of 26 Cases Confirms Recurrent NCOA1–3 Rearrangement. *Am J Surg Pathol*. 2020;44:30–42. [PubMed: 31464709]
  11. Bekers EM, Groenen P, Verdijk MAJ, Raaijmakers-van Geloof WL, Roepman P, Vink R, et al. Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. *Genes Chromosomes Cancer*. 2017;56:750–57. [PubMed: 28639284]
  12. Lin DI, Hemmerich A, Edgerly C, Duncan D, Severson EA, Huang RSP, et al. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. *Gynecol Oncol*. 2020;157:357–66. [PubMed: 32156473]
  13. Kommos FK, Chang KT, Stichel D, Banito A, Jones DT, Heilig CE, et al. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. *J Pathol Clin Res*. 2020;6:178–84. [PubMed: 32352245]
  14. Lee JC, Lu TP, Changou CA, Liang CW, Huang HN, Lauria A, et al. Genome wide copy number analysis of Mullerian adenosarcoma identified chromosomal instability in the aggressive subgroup. *Mod Pathol*. 2016;29:1070–82. [PubMed: 27255164]
  15. Hodgson A, Amemiya Y, Seth A, Djordjevic B, Parra-Herran C. High-grade Mullerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior. *Am J Surg Pathol*. 2017;41:1513–22. [PubMed: 28834809]
  16. Howitt BE, Sholl LM, Dal Cin P, Jia Y, Yuan L, MacConaill L, et al. Targeted genomic analysis of Mullerian adenosarcoma. *J Pathol*. 2015;235:37–49. [PubMed: 25231023]
  17. Piscuoglio S, Burke KA, Ng CK, Papanastasiou AD, Geyer FC, Macedo GS, et al. Uterine adenosarcomas are mesenchymal neoplasms. *J Pathol*. 2016;238:381–8. [PubMed: 26592504]
  18. Patel SB, McCormack C, Hodge JC. Non-fusion mutations in endometrial stromal sarcomas: what is the potential impact on tumourigenesis through cell cycle dysregulation? *Journal of clinical pathology*. 2020. doi: 10.1136/jclinpath-2020-206432
  19. Przybyl J, Kidzinski L, Hastie T, Debiec-Rychter M, Nusse R, van de Rijn M. Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway. *Gynecol Oncol*. 2018;149(2):388–93. [PubMed: 29544705]



**Figure 1.** Histomorphology of the uterine (case 1, A-C) and vaginal (case 2, E-F) tumors. The uterine tumor shows short spindle to ovoid cells with alternating cellularity (A), vague short fascicles, cellular aggregates of primitive cells, and myxoid to hyalinized stroma in the hypocellular area (C). The vaginal tumor shows monomorphic spindle cells with alternating cellularity and rich vasculature (D), in whorling (D) to storiform (E) patterns. NCOA2 immunostaining shows diffuse moderate staining (F).



**Figure 2.** Histomorphology of the scrotal (case 3, A-B), para-rectal (case 4, C-D), and two renal tumors (case 5, E-F; case 6, G-H). The superficial scrotal tumor shows mildly infiltrative border (A) and is composed of compact spindle cells in storiform pattern (B), mimicking dermatofibrosarcoma protuberans. The para-rectal tumor shows solid sheets of ovoid cells (C) with vesicular chromatin and indistinct cell border, accompanied by microcystic spaces (D). Case 5 shows vague fascicular pattern (E) and areas with increased pleomorphism and


hyperchromasia (F). Case 6 displays sheets of ovoid cells with variation in cellularity (G). Epithelioid cells were observed in recurrent lesion (H).

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3.** Molecular findings of *MEIS1-NCOA* sarcomas. (A) Left panel, chromosomal locations and transcription directions of *MEIS1* (2p14), *NCOA1* (2p23.3), and *NCOA2* (8q13.3) genes. Right panel, schematic diagram illustrating variants of *MEIS1-NCOA2/1* fusions transcripts, including exon 6 of *MEIS1* fused to exon 12 of *NCOA2*, exon 7 of *MEIS1* fused to exon 13 or 14 of *NCOA2*, and exon 7 of *MEIS1* fused to exon 13 of *NCOA1*. All the fusion variants are in-frame, as demonstrated by the fusion junction sequences and predicted amino acid beneath each fusion variant. (B-C) Representative FISH of *MEIS1* (B) and *NCOA2* (C) of case 3 showing break-apart of orange and green signals (arrows).



**Figure 4.** A rhabdomyosarcoma of the vulva with *MEIS1-NCOA2* fusion. The tumor is composed of spindle cells in intersecting short fascicles (A). Some of the tumor cells have increased amount of eosinophilic cytoplasm (B).

**Table 1.**Clinicopathologic parameters of sarcomas with *MEIS1-NCOA2/1* fusion

		Age	Sex	Location	Size (cm)	Original diagnosis	Necrosis	Mitosis (/10HPFs)	Fusion junction	Follow-up
?? Unclassified sarcoma										
ESS182/MYO622	1	58	F	Uterine corpus	20	Undifferentiated uterine sarcoma	N	33	<i>MEIS1</i> ex7- <i>NCOA2</i> ex13	Mets (mesentery, 5m)
RMS368 *	2	35	F	Vagina	11	Low-grade endometrial stromal sarcoma	N	<1	<i>MEIS1</i> ex6- <i>NCOA2</i> ex12	LR (3m, 1.5y, 7.5y)
DFSP99/RMS363 *	3	76*	M	Scrotum	NA (LR: 0.6) <sup>‡</sup>	Low-grade sarcoma, NOS (LR)	N	2–3	?	LR (several ys)
ME653 *	4	38	F	Para-rectal	14	Sarcoma, NOS	N	8	?	LR (4y, 6y, 8y)
SBRCT1204	5	20	F	Kidney	21	Undifferentiated spindle cell sarcoma	Y (10%)	25	<i>MEIS1</i> ex7- <i>NCOA1</i> ex13	NA
SBRCT1205	6	50	F	Kidney and 2 add ST implants	19	Sarcoma, NOS	Y	10	<i>MEIS1</i> ex7- <i>NCOA2</i> ex14	LR (1.5y, 6y)
SS100/ref *	#	72	F	Kidney	4	Mixed epithelial stromal tumor with atypia	N	4	<i>MEIS1</i> ex7- <i>NCOA2</i> ex13/14	NED (9m)
/ref	#	21	M	Kidney	15	Undifferentiated sarcoma	Y	13	NA	NA
?? Spindle cell rhabdomyosarcoma										
RMS322	1	33	F	Vulva	2.5	spRMS	NA	10–20	<i>MEIS1</i> ex7- <i>NCOA2</i> ex13	NA
RMS391 *				Iliac bone		spRMS				
*/ref	‡	22	M	Iliac bone		spRMS	Y	18	<i>MEIS1</i> ex6- <i>NCOA2</i> ex12	NED (8m)
/ref	‡	39	M	Iliac bone		spRMS		50	NA	

LR, local recurrence; NA, not available; HPF, high power fields; F, female; M, male; N, not present; Y, present; ex, exon; Mets, metastasis; m, months; y, years; NED, no evidence of disease; spRMS, spindle cell rhabdomyosarcoma; NOS, not otherwise specified; \*, tested by Trusight RNAseq platform

\* age at recurrence

# previously reported [ref: 30179902]

‡ size of the recurrent lesion

‡ previously reported [ref: 30720533]